Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer

Sponsor
National Cancer Institute (NCI)
Study ID
NCT00253526
Phase
PHASE2
Status
Withdrawn

Conditions

  • Adenocarcinoma of the Pancreas
  • Recurrent Pancreatic Cancer
  • Stage I Pancreatic Cancer
  • Stage II Pancreatic Cancer
  • Stage III Pancreatic Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • bevacizumab — DRUG
  • gemcitabine hydrochloride — DRUG
  • adjuvant therapy — PROCEDURE
  • anti-cytokine therapy — PROCEDURE
  • antiangiogenesis therapy — PROCEDURE
  • antibody therapy — PROCEDURE
  • biological therapy — PROCEDURE
  • chemotherapy — PROCEDURE
  • conventional surgery — PROCEDURE
  • growth factor antagonist therapy — PROCEDURE
  • monoclonal antibody therapy — PROCEDURE
  • surgery — PROCEDURE

Study Details

RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells an help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of pancreatic cancer by blocking blood flow to the tumor. Giving gemcitabine hydrochloride together with bevacizumab after surgery may kill any remaining tumor cells. PURPOSE: This phase II trial is studying gemcitabine hydrochloride and bevacizumab to see how well they work compared to gemcitabine hydrochloride alone in treating patients who are undergoing surgery for pancreatic cancer.

Key Dates

First listed
Nov 15, 2005
Status verified
Dec 2006

Study Design

Enrollment
0 participants (actual)
Primary purpose
TREATMENT

Related Studies